Lisaftoclax clinical trials
Also written APG-2575.
How each study uses Lisaftoclax is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Lisaftoclax studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
32 studies that test it; most in 2026 (12)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 16 · Other 16
Ascentage Pharma Group Inc. (16) · Institute of Hematology & Blood Diseases Hospital, China (4) · First Affiliated Hospital of Zhejiang University (2) · Henan Cancer Hospital (2) · Guangdong Second Provincial General Hospital (1) · LanZhou University (1) · Peking University First Hospital (1) · The Affiliated People's Hospital of Ningbo University (1)
Often tested with
Tested in the same studies.
Aclarubicin (2) · Tucidinostat (1) · Olverembatinib (1) · Dexamethasone (1) · Ivosidenib (1) · Venetoclax (1) · Gilteritinib (1) · Homoharringtonine (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 6, 2 in phase 3
Studies that test Lisaftoclax, phase 3 first.
- Dec 2026Global Trial in APG2575 for Patients With CLL/SLLPhase 3 · Ascentage Pharma Group Inc.
- Aug 2027A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.Phase 3 · Ascentage Pharma Group Inc.
- Dec 2026Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLPhase 2 · Ascentage Pharma Group Inc.
- Dec 2026Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLPhase 1 · Institute of Hematology & Blood Diseases Hospital, China
- Jul 2027Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaPhase 2 · Henan Cancer Hospital
- Sep 2027Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailurePhase 2 · Guangdong Second Provincial General Hospital
Studies
Open first, then newest update. How each study uses Lisaftoclax is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 32
- Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).RecruitingPhase 3Ascentage Pharma Group Inc.NCT06641414Written as Lisaftoclax (APG-2575)How we know
- Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLLNot yet recruitingPhase 2Institute of Hematology & Blood Diseases Hospital, ChinaNCT07831395Written as Lisaftoclax (APG-2575)How we know
- Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy FailureEnrolling by invitationPhase 2Guangdong Second Provincial General HospitalNCT07813390Written as Lisaftoclax (APG-2575)How we know
- A Single-center, Prospective, Exploratory Clinical StudyNot yet recruitingNot applicableLanZhou UniversityNCT07795099Written as LisaftoclaxHow we know
- Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALLRecruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT05495035Written as Olverembatinib, APG-2575, DexamethasoneHow we know
- Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid LeukemiaRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06265545Written as LisaftoclaxHow we know
- Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell LymphomaNot yet recruitingPhase 2Henan Cancer HospitalNCT07459608Written as LisaftoclaxHow we know
- A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.RecruitingPhase 3Ascentage Pharma Group Inc.NCT06319456Written as Lisaftoclax (APG-2575)How we know
- Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRecruitingPhase 2Ruijin HospitalNCT07272499Written as Lisaftoclax (APG-2575)How we know
- Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL)Not yet recruitingPhase 2Peking University First HospitalNCT07717580Written as Lisaftoclax (APG-2575)How we know
- Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of RelapseNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07686965Written as Lisaftoclax Plus AzacitidineHow we know
- Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted TherapyNot yet recruitingPhase 2Henan Cancer HospitalNCT07684950Written as LisaftoclaxHow we know
- Lisaftoclax for Prevention of Differentiation Syndrom in Acute Promyelocytic Leukemia PatientsNot yet recruitingPhase 2/3The Affiliated People's Hospital of Ningbo UniversityNCT07597941Written as Lisaftoclax (APG-2575)How we know
- Global Trial in APG2575 for Patients With CLL/SLLRecruitingPhase 3Ascentage Pharma Group Inc.NCT06104566Written as lisaftoclax +BTK inhibitorHow we know
- Comparing the Efficacy of LDA, LHAA, and LA Regimens in Young Adults With Intermediate- and High-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651163Written as Lisaftoclax+daunorubicin+cytarabineHow we know
- Comparing the Efficacy of the LDA, LHAA, and DA Regimens in Young Adults With Low-Risk Acute Myeloid Leukemia Eligible for Intensive ChemotherapyEnrolling by invitationPhase 2/3First Affiliated Hospital of Zhejiang UniversityNCT07651176Written as Lisaftoclax+daunorubicin+cytarabineHow we know
- Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07601607Written as LisaftoclaxHow we know
- Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AMLRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT04501120Written as Lisaftoclax (APG-2575)How we know
- Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLLRecruitingPhase 2Ascentage Pharma Group Inc.NCT05147467Written as APG2575How we know
- A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.RecruitingPhase 1/2Ascentage Pharma Group Inc.NCT06182969Written as APG-2575How we know
See all 32 studies that test Lisaftoclax →
Given beside what is tested · 3 — Lisaftoclax is usual care or a partner of the new treatment
- APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid TumorsRecruitingPhase 1/2Ascentage Pharma Group Inc.NCT05701306Written as APG-2575How we know
- Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II StudyNot yet recruitingPhase 1/2Sun Yat-sen UniversityNCT07398638Written as LisaftoclaxHow we know
- A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHLRecruitingPhase 2Ascentage Pharma Group Inc.NCT04496349Written as APG-2575How we know
Codes
What other systems call Lisaftoclax · ClinicalTrials.gg INT002005
- MeSH (NLM) C000726452LisaftoclaxOne source ClinicalTrials.gov
- UNII (FDA) OSL3FEZ1IFLISAFTOCLAXConfirmed FDA, Wikidata
- Wikidata Q124721221lisaftoclaxConfirmed FDA, Wikidata
- NCI Thesaurus C156249LisaftoclaxOne source FDA
- DrugBank DB18054One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000726452 | Lisaftoclax | One source ClinicalTrials.gov |
| UNII (FDA) | OSL3FEZ1IF | LISAFTOCLAX | Confirmed FDA, Wikidata |
| Wikidata | Q124721221 | lisaftoclax | Confirmed FDA, Wikidata |
| NCI Thesaurus | C156249 | Lisaftoclax | One source FDA |
| DrugBank | DB18054 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.